FDA names MB-101 US orphan drug for certain types of glioma

FDA names MB-101 US orphan drug for certain types of glioma

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MB-101, a CAR T-cell therapy being developed by Mustang Bio to treat certain forms of malignant glioma, a class of rare brain cancers. Orphan drug status is given to therapies that are intended to treat, diagnose, or prevent rare diseases, defined in the U.S. as those affecting fewer than 200,000 people. This designation provides incentives to encourage companies …